1-(3-(4-氟苯基)异恶唑-5-基)乙醇 | 1429330-61-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(3-(4-氟苯基)异恶唑-5-基)乙醇
• 英文名称: 1-(3-(4-fluorophenyl)isoxazol-5-yl)ethanol
• 英文别名: 1-(3-(4-fluorophenyl)isoxazol-5-yl)ethan-1-ol；1-(3-(4-Fluorophenyl)isoxazol-5-yl)ethanol；1-[3-(4-fluorophenyl)-1,2-oxazol-5-yl]ethanol
• CAS: 1429330-61-9
• 化学式: C₁₁H₁₀FNO₂
• 分子量: 207.204
• InChiKey: MLKHPWDFVDCXQZ-UHFFFAOYSA-N

物化性质

• 沸点：
  367.3±37.0 °C(Predicted)
• 密度：
  1.248±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(3-(4-氟苯基)异恶唑-5-基)乙醇 在 正丁基锂 、 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 18.17h， 生成 3-(4-fluorophenyl)-5-(1-(pyridin-4-yl)ethyl)isoxazole
  参考文献：
  名称：

  [EN] PYRIDINE DERIVATIVES
  [FR] DÉRIVÉS PYRIDINES

  摘要：

  本申请提供了新型的吡啶化合物及其药用可接受的盐或前药。同时，还提供了制备这些化合物的方法。这些化合物通过向患者施用一种或多种化合物的治疗有效量，用于抑制CYP 17活性。通过这样做，这些化合物有效地治疗与CPY17活性相关的病症。可以使用这些化合物治疗多种病症，包括以异常细胞增殖为特征的疾病。在一个实施例中，所述疾病为癌症，如前列腺癌。

  公开号：

  WO2013049559A1
• 作为产物：
  描述：

  对氟苯甲醛 在 盐酸羟胺 、 sodium carbonate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 1-(3-(4-氟苯基)异恶唑-5-基)乙醇
  参考文献：
  名称：

  [EN] PYRIDINE DERIVATIVES
  [FR] DÉRIVÉS PYRIDINES

  摘要：

  本申请提供了新型的吡啶化合物及其药用可接受的盐或前药。同时，还提供了制备这些化合物的方法。这些化合物通过向患者施用一种或多种化合物的治疗有效量，用于抑制CYP 17活性。通过这样做，这些化合物有效地治疗与CPY17活性相关的病症。可以使用这些化合物治疗多种病症，包括以异常细胞增殖为特征的疾病。在一个实施例中，所述疾病为癌症，如前列腺癌。

  公开号：

  WO2013049559A1

文献信息

• PYRIDINE DERIVATIVES
  申请人：Asana BioSciences, LLC

  公开号：US20170073339A1

  公开（公告）日：2017-03-16

  The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.

  本申请提供了新型吡啶化合物及其药学上可接受的盐或前药。还提供了制备这些化合物的方法。通过向患者投入一种或多种化合物的治疗有效剂量，这些化合物可用于抑制CYP17活性。通过这样做，这些化合物可有效治疗与CYP17活性有关的疾病。这些化合物可用于治疗多种疾病，包括以异常细胞增殖为特征的疾病。在一种实施方式中，该疾病是癌症，如前列腺癌。
• Pyridine Derivatives
  申请人：Endo Pharmaceuticals Inc.

  公开号：US20130085148A1

  公开（公告）日：2013-04-04

  The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CPY17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.

  本申请提供了新型吡啶化合物及其药学上可接受的盐或前药。同时还提供了制备这些化合物的方法。这些化合物可以通过向患者投予治疗有效量的一个或多个化合物来抑制CYP17活性。通过这样做，这些化合物对于治疗与CPY17活性相关的疾病是有效的。这些化合物可以用于治疗各种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症，如前列腺癌。
• Pyridine derivatives
  申请人：Endo Pharmaceuticals, Inc.

  公开号：US08809372B2

  公开（公告）日：2014-08-19

  The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.

  本申请提供了新型吡啶化合物及其药学上可接受的盐或前药。还提供了制备这些化合物的方法。这些化合物可通过向患者投予治疗有效量的一个或多个化合物来抑制CYP17活性。通过这样做，这些化合物可有效治疗与CYP17活性有关的疾病。这些化合物可用于治疗多种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症，如前列腺癌。
• Pd-catalyzed heteroannulation of isoxazoles: Convergent synthesis of isoxazolo[5,4-c]quinolines
  作者：Ekaterina E. Galenko、Timur O. Zanakhov、Mikhail S. Novikov、Alexander F. Khlebnikov

  DOI：10.1016/j.tetlet.2022.154270

  日期：2023.1

  Variously substituted isoxazolo[5,4-c]quinolines can be easily prepared in high yields by Pd-catalyzed heteroannulation of 5-carbonyl-4-haloisoxazoles with 2-aminophenylboronic acid derivatives. 4-Unsubstituted isoxazolo[5,4-c]quinolines can be readily modified at C4 via a chlorination/substitution sequence.

  通过 Pd 催化的 5-羰基-4-卤代异恶唑与 2-氨基苯基硼酸衍生物的杂环化，可以很容易地以高产率制备各种取代的异恶唑并 [5,4- c ] 喹啉。4-未取代的异恶唑并 [5,4- c ] 喹啉可以很容易地通过氯化/取代顺序在 C4 处进行修饰。
• MODIFIED CONJUGATED DIENE RUBBER, METHOD FOR PRODUCING SAME, AND RUBBER COMPOSITION
  申请人：Tanaka Ryouji

  公开号：US20130085228A1

  公开（公告）日：2013-04-04

  By a method comprising a process including (a) producing a modified conjugated diene polymer through reaction of a conjugated diene polymer having an alkali metal or alkaline-earth metal active terminal with a first alkoxysilane compound which has both an alkoxysilyl group and at least one group convertible into an onium, and (b) mixing the modified conjugated diene polymer, an agent for producing onium, a second alkoxysilane compound having an alkoxysilyl group and at least one group convertible into an onium and a condensation catalyst containing metal element(s) for alkoxysilane compounds, conjugated diene rubber usable as a starting material of cross-linked rubber which is used for a tire tread or the like and allows enhancement of low fuel consumption property can be obtained.